Controlling the Growth of the Skin Commensal Staphylococcus epidermidis Using d -Alanine Auxotrophy

Abstract

The skin microbiome is rich in opportunities for novel therapeutics for skin diseases, and synthetic biology offers the advantage of providing novel functionality or therapeutic benefit to live biotherapeutic products. The development of novel bacterial strains whose growth can be controlled without the use of antibiotics or genetic elements conferring antibiotic resistance enables modulation of therapeutic exposure and improves safety. This study presents the design and in vitro evidence of a skin commensal whose growth can be controlled through d- alanine. The basis of this strain will support future clinical studies of this strain in humans.